close
The Wayback Machine - https://web.archive.org/web/20210308212959/https://www.tropmedres.ac/
Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research Highlights

  • Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border

    Posted 05/03/2021. Prevention of mother to child transmission of Hepatitis B can be challenging in resource limited settings. Marieke Bierhoff and colleagues look at strategies that might be more feasible in these settings. TDF (tenofovir disoproxil fumarate) after rapid diagnostic test may be a more feasible strategy to implement in resource limited settings, TDF after hepatitis B e-antigen test is a cheaper option.

  • Effectiveness of a sepsis programme in a resource-limited setting

    Posted 02/03/2021. Direk Limmathurotsakul and colleagues show that a Sepsis Fast Track (SFT) programme, implemented in Thailand to screen, initiate sepsis care and fast-track them when applicable to ICU upon admission, are associated with higher chances of survival. We analyzed data of a prospective observational study, having control group from both pre and post-intervention periods.

  • Human, animal, water source interactions and leptospirosis in Thailand

    Posted 09/02/2021. Wirichada Pan-ngum and colleagues address key knowledge gaps on human-animal-water-source interactions and leptospirosis in high-risk settings, Thailand. Water-source sharing networks and human–animal contact patterns are key information potentially involved in the epidemiology of leptospirosis. Occupations related to animals/environmental water and consuming water from more than two sources increased the risk exposure to leptospirosis.

More research highlights

The COPCOV Trial’s position statement on “A living WHO guideline on drugs to prevent COVID-19.”

Following WHO recommendations against the use of hydroxychloroquine in the prevention of COVID-19, including its use in controlled trials, we are reviewing the guideline and available evidence. We are concerned that this judgement from the authors of the guideline is scientifically unsound.

Read the full statement (PDF)